Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 1
2006 2
2009 3
2010 4
2011 2
2012 5
2013 6
2014 6
2015 23
2016 22
2017 31
2018 53
2019 48
2020 47
2021 48
2022 33
2023 26
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

334 results

Results by year

Filters applied: . Clear all
Page 1
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
Lowenthal ED, Chapman J, Ohrenschall R, Calabrese K, Baltrusaitis K, Heckman B, Yin DE, Agwu AL, Harrington C, Van Solingen-Ristea RM, McCoig CC, Adeyeye A, Kneebone J, Chounta V, Smith-Anderson C, Camacho-Gonzalez A, D'Angelo J, Bearden A, Crauwels H, Huang J, Buisson S, Milligan R, Ward S, Bolton-Moore C, Gaur AH; IMPAACT 2017 Collaborators; IMPAACT 2017 Team. Lowenthal ED, et al. Lancet HIV. 2024 Apr;11(4):e222-e232. doi: 10.1016/S2352-3018(23)00301-6. Lancet HIV. 2024. PMID: 38538161 Clinical Trial.
Cost-effectiveness of broadly neutralizing antibodies for infant HIV prophylaxis in settings with high HIV burdens: a simulation modeling study.
Alba C, Malhotra S, Horsfall S, Barnhart ME, Bekker A, Chapman K, Cunningham CK, Fast PE, Fouda GG, Freedberg KA, Goga A, Ghazaryan LR, Leroy V, Mann C, McCluskey MM, McFarland EJ, Muturi-Kioi V, Permar SR, Shapiro R, Sok D, Stranix-Chibanda L, Weinstein MC, Ciaranello AL, Dugdale CM. Alba C, et al. medRxiv [Preprint]. 2023 Nov 7:2023.11.06.23298184. doi: 10.1101/2023.11.06.23298184. medRxiv. 2023. PMID: 37986879 Free PMC article. Preprint.
Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s.
Van Schalkwyk M, Bekker A, Decloedt E, Wang J, Theron GB, Cotton MF, Eke AC, Cressey TR, Shapiro DE, Bacon K, Knowles K, George K, Browning R, Chakhtoura N, Rungruengthanakit K, Wiesner L, Capparelli EV, Stek AM, Mirochnick M, Best BM; IMPAACT P1026s Protocol Team. Van Schalkwyk M, et al. Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0073723. doi: 10.1128/aac.00737-23. Epub 2023 Oct 26. Antimicrob Agents Chemother. 2023. PMID: 37882552 Free PMC article.
Metabolomic profiling of preterm birth in pregnant women living with HIV.
Tobin NH, Murphy A, Li F, Brummel SS, Fowler MG, Mcintyre JA, Currier JS, Chipato T, Flynn PM, Gadama LA, Saidi F, Nakabiito C, Koos BJ, Aldrovandi GM; IMPAACT 1077BF/1077FF PROMISE Study Team. Tobin NH, et al. Metabolomics. 2023 Oct 25;19(11):91. doi: 10.1007/s11306-023-02055-1. Metabolomics. 2023. PMID: 37880481 Free PMC article.
Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial.
Gupta A, Singh P, Aaron L, Montepiedra G, Chipato T, Stranix-Chibanda L, Chanaiwa V, Vhembo T, Mutambanengwe M, Masheto G, Raesi M, Bradford S, Golner A, Costello D, Kulkarni V, Shayo A, Kabugho E, Jean-Phillippe P, Chakhtoura N, Sterling TR, Theron G, Weinberg A; IMPAACT P1078 TB APPRISE Study Team. Gupta A, et al. Lancet Child Adolesc Health. 2023 Oct;7(10):708-717. doi: 10.1016/S2352-4642(23)00174-8. Epub 2023 Aug 24. Lancet Child Adolesc Health. 2023. PMID: 37634517 Clinical Trial.
Risk Factors for Perinatal Transmission of Hepatitis C Virus.
Prasad M, Saade GR, Clifton RG, Sandoval GJ, Hughes BL, Reddy UM, Bartholomew A, Salazar A, Chien EK, Tita ATN, Thorp JM Jr, Metz TD, Wapner RJ, Sabharwal V, Simhan HN, Swamy GK, Heyborne KD, Sibai BM, Grobman WA, El-Sayed YY, Casey BM, Parry S, Rathore M, Diaz-Velasco R, Puga AM, Wiznia A, Kovacs A, Garry DJ, Macones GA; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network*. Prasad M, et al. Obstet Gynecol. 2023 Sep 1;142(3):449-456. doi: 10.1097/AOG.0000000000005306. Obstet Gynecol. 2023. PMID: 37590978
334 results